Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This will be the first prospective study where patients will be selected on the basis of two
measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess
prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy
in highly selected patients with EGFR overexpression and/or EGFR amplification.